Medications for Autosomal Recessive Hypotrichosis
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Autosomal Recessive Hypotrichosis.
Found 8 Approved Drugs for Autosomal Recessive Hypotrichosis
Finasteride
Brand Names
Propecia, Proscar
Finasteride
Brand Names
Propecia, Proscar
Form: Tablet
Method of administration: Oral
FDA approval date: December 15, 2006
Classification: 5-alpha Reductase Inhibitor
PROSCAR, is a 5α-reductase inhibitor, indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to.
Olumiant
Generic Name
Baricitinib
Olumiant
Generic Name
Baricitinib
Form: Tablet
Method of administration: Oral
FDA approval date: May 31, 2018
Classification: Janus Kinase Inhibitor
OLUMIANT ® is a Janus kinase (JAK) inhibitor indicated for: the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more TNF blockers.
Litfulo
Generic Name
Ritlecitinib
Litfulo
Generic Name
Ritlecitinib
Form: Capsule
Method of administration: Oral
FDA approval date: July 06, 2023
Classification: Kinase Inhibitor
LITFULO is a kinase inhibitor indicated for the treatment of severe alopecia areata in adults and adolescents 12 years and older. Limitations of Use : Not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine or other potent immunosuppressants. LITFULO is a kinase inhibitor indicated for the treatment of severe alopecia areata in adults and adolescents 12 years and older. ( 1 ) Limitations of Use : Not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine or other potent immunosuppressants ( 1 ).
Bimatoprost
Brand Names
Lumigan, Latisse, Durysta
Bimatoprost
Brand Names
Lumigan, Latisse, Durysta
Form: Implant, Solution
Method of administration: Intracameral, Ophthalmic
FDA approval date: January 26, 2009
Classification: Prostaglandin Analog
LUMIGAN ® (bimatoprost ophthalmic solution)
Leqselvi
Generic Name
Deuruxolitinib
Leqselvi
Generic Name
Deuruxolitinib
Form: Tablet
Method of administration: Oral
FDA approval date: June 25, 2025
Classification: Janus Kinase Inhibitor
LEQSELVI™ is indicated for the treatment of adult patients with severe alopecia areata. Limitations of Use LEQSELVI is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine, or other potent immunosuppressants. LEQSELVI is a Janus kinase (JAK) inhibitor indicated for the treatment of adults with severe alopecia areata. ( 1 ) Limitations of Use: LEQSELVI is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine or other potent immunosuppressants. ( 1 )
Showing 1-5 of 8
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances